{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-039772","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2023-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.417628+00:00","generated_at":"2026-06-19T11:46:08.986241+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AlloVir reports FY2022 net loss of $168.7M and positive Phase 2 posoleucel data in kidney transplant","bullets":["FY2022 net loss $168.7M ($2.20/share); R&D spend $118.9M; cash & securities $233.8M as of Dec 31, 2022.","2023 operating expense guidance of $150-170M (excl. non-cash); Phase 3 enrollment completion expected by end of 2023 with 2024 data.","Phase 2 study: posoleucel achieved ≥1-log viral load reduction in 39% vs 14% placebo; biweekly dosing 50%.","In high viral load (≥10,000 copies/mL): 69% posoleucel vs 25% placebo achieved ≥1-log reduction; 75% for biweekly dosing.","Posoleucel well tolerated with balanced safety; no GVHD, cytokine release syndrome, or treatment-related acute rejection."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-039772","json":"https://secwatch.observer/filing/0001193125-23-039772.json","markdown":"https://secwatch.observer/filing/0001193125-23-039772.md","text":"https://secwatch.observer/filing/0001193125-23-039772.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523039772/0001193125-23-039772-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523039772/d468482d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T11:46:08.986241+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b89418323bfb7b2b0bc97540072af3c3839032c","claim":"Kalaris Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2022.","evidence_excerpt":"On February 15, 2023, AlloVir, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523039772/0001193125-23-039772-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}